美国斥20亿美元向辉瑞额外购买1亿剂疫苗
美国政府将向辉瑞(PFE.US)支付近20亿美元,以购买1亿剂额外的新冠疫苗。
根据新协议,辉瑞将在明年6月30日之前交付至少7,000万剂,其余不迟於7月31日交付,令美国总购买剂量达到2亿剂,涉资约40亿美元。
美国每剂的购买价格为19.5美元,略高於欧盟的18.9美元。
根据美国疾控中心(CDC)的数据,截至周一已有逾60万名美国人接种第一批疫苗,主要为医护人员、入住疗养院人士以及部分政府高级官员。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.